Skip to main content
Ralf Bargou on Muck Rack

Ralf Bargou

As seen in: Nature, Cancer Treatment Reviews
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ralf

Contact Ralf, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Author Correction: 7-Dehydrocholesterol is an endogenous suppressor of ferroptosis

|
By Florencio Porto Freitas, Hamed Alborzinia, Palina Nepachalovich, Lohans Pedrera, Omkar Zilka, Alex Inague, Corinna Klein, Nesrine Aroua, Kamini Kaushal, Bettina Kast, Svenja Lorenz, Zhiyi Chen, Sena Atici, Sebastian Doll, Emily Schaefer, Werner Schmitz, Peter Imming, Sayuri Miyamoto, Ann M. Wehman, Karoly Mirnics, Lokender Kumar, Judith Klein-Seetharaman, Svenja Meierjohann, Isabel Weigand, Matthias Kroiss, Georg W. Bornkamm, Fernando Gomes, Manjima B Sathian, David B. Konrad, Douglas Covey, Bernhard Michalke, Kurt Bommert, Ralf Bargou, Ana J. García-Sáez, Derek Pratt, Maria Fedorova, Andreas Trumpp, Marcus Conrad, Viktoria Kunz, Helene Nehring, Ifedapo Ekpo, Aline Horling, Thiago C. Genaro-Mattos
| Nature Verified
Correction to: Nature https://doi.org/10.1038/s41586-023-06878-9 Published online 31 January 2024 In the originally published version of this article, the blank values in Extended Data Fig. 2a,b correspond to background fluorescence measurements of a stable commercial resazurin solution (AquaBluer Cell Viability Assay Solution, Multi-Target Pharmaceuticals, cat. no. 6015), diluted in complete culture medium.
Open in Who Shared Issue with article?

VS-4718 enhances apoptosis induced by low-dose carfilzomib and overcomes carfilzomib resistance in PSMB5 -mutated proteasome inhibitor resistant multiple myeloma

|
By Sofia Catalina Heredia-Guerrero, Marietheres Evers, Thorsten Stühmer, Ralf Bargou, Andreas Rosenwald, Manik Chatterjee, Daniela Brünnert, Ellen Leich-Zbat, Tina Grieb, Hilka Rauert-Wunderlich
| Nature Verified
Abstract The introduction of proteasome inhibitors (PIs) into multiple myeloma (MM) treatment has substantially improved therapeutic options and survival rates. However, the development of resistance to PIs as well as serious side effects of PI treatment continue to justify the search for effective, less burdensome combination therapies.
Open in Who Shared Issue with article?

Riboflavin metabolism shapes FSP1-driven ferroptosis resistance

|
By Izadora de Souza, Biplab Ghosh, Florencio Porto Freitas, Zhiyi Chen, Shibo Sun, Palina Nepachalovich, Juliane Tschuck, Apoorva Mathur, Ariane Nunes-Alves, Jannik Buhr, Camilo Aponte-Santamaría, Werner Schmitz, Matthias Mack, Martin Eilers, Ralf Bargou, Milena Chaufan, Mayher Kaur, Mario Palma, Jessalyn M. Ubellacker, Ulrich Elling, Hellmut G. Augustin, Kamyar Hadian, Svenja Meierjohann, Bettina Proneth, Marcus Conrad, Maria Fedorova, Hamed Alborzinia, Vera Skafar, Merce Donate Castillo, Lars Seufert, Sebastian Bothe
| Nature Verified
Abstract Membrane protection against oxidative insults is achieved by the concerted action of glutathione peroxidase 4 (GPX4) and endogenous lipophilic antioxidants such as ubiquinone and vitamin E. More recently, ferroptosis suppressor protein 1 (FSP1) was identified as a critical ferroptosis inhibitor, acting via the regeneration of membrane-embedded antioxidants.
Open in Who Shared Issue with article?
See all 11 articles